Acute ischemic stroke is the most common type of stroke, accounting for about 60%-80% of all
stroke, with high incidence, high mortality, high disability rate, has become the first cause
of death in China. At present, only ultra-early thrombolytic therapy, endovascular therapy
and antiplatelet therapy have obtained evidence-based medical evidence in ischemic stroke
treatment, but only thrombolytic therapy and endovascular therapy can improve the good
prognosis of patients. Intravenous thrombolytic therapy within 4.5 hours after the onset of
ischemic stroke symptoms has been shown to be effective, which is recommended in the
guidelines.
In most countries, alteplase (R-tPA) is the only drug approved for the treatment of acute
ischemic stroke. Recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA) is a
modified recombinant tissue-type plasminogen activator, with no procoagulant effect and a
longer half life. In recent years, there are some studies on the comparison of therapeutic
effects of TNK-tPA and RT-PA in patients with acute ischemic stroke, and TNK shows promising
especially for large artery occlussion. At present, there are few reports on the application
of rhTNK-tPA in Chinese stroke patients.
The aim of this study is to evaluate the efficacy and safety of rhTNK-tPA in Chinese patients
with ischemic stroke in a prospective, multicenter registration study.